Incyte Corp Insider Trading
Every director, officer and 10% holder of Incyte Corp has to report each trade in its stock within two business days of making it. This is those filings.
INCY on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Pablo J CagnoniPresident, Global Head of R&D2026-09-159.2K shat $120.50 | Sale10b5-1 plan | $1.1M |
| Pablo J CagnoniPresident, Global Head of R&D2026-09-1514K shat $120.49 | Sale10b5-1 plan | $1.7M |
| Pablo J CagnoniPresident, Global Head of R&D2026-08-1910.8K shat $125.56 | Sale10b5-1 plan | $1.4M |
| Pablo J CagnoniPresident, Global Head of R&D2026-08-1210.8K shat $120.04 | Sale10b5-1 plan | $1.3M |
| Patrick A MayesEVP & Chief Scientific Officer2026-08-052.2K shat $123.99 | Sale10b5-1 plan | $273.6K |
| Pablo J CagnoniPresident, Global Head of R&D2026-08-0510.6K shat $122.69 | Sale10b5-1 plan | $1.3M |
| Patrick A MayesEVP & Chief Scientific Officer2026-08-036.1K shat $120.43 | Sale10b5-1 plan | $729.2K |
| Patrick A MayesEVP & Chief Scientific Officer2026-07-3114.7K shat $119.46 | Sale10b5-1 plan | $1.8M |
| Patrick A MayesEVP & Chief Scientific Officer2026-07-315.3K shat $119.42 | Sale10b5-1 plan | $636.7K |
| Patrick A MayesEVP & Chief Scientific Officer2026-07-312.2K shat $119.47 | Sale10b5-1 plan | $261.3K |
| Patrick A MayesEVP & Chief Scientific Officer2026-07-316.2K shat $119.43 | Sale10b5-1 plan | $737K |
| Patrick A MayesEVP & Chief Scientific Officer2026-07-314.7K shat $119.39 | Sale10b5-1 plan | $560.5K |
| Patrick A MayesEVP & Chief Scientific Officer2026-07-312.9K shat $119.40 | Sale10b5-1 plan | $342K |
| Patrick A MayesEVP & Chief Scientific Officer2026-07-311.6K shat $119.51 | Sale10b5-1 plan | $196.4K |
| Patrick A MayesEVP & Chief Scientific Officer2026-07-311.6K shat $119.38 | Sale10b5-1 plan | $196K |
| Patrick A MayesEVP & Chief Scientific Officer2026-07-3185 shat $122.19 | Sale10b5-1 plan | $10.4K |
| Patrick A MayesEVP & Chief Scientific Officer2026-07-31326 shat $121.69 | Sale10b5-1 plan | $39.7K |
| Patrick A MayesEVP & Chief Scientific Officer2026-07-312.3K shat $119.41 | Sale10b5-1 plan | $273.8K |
| Pablo J CagnoniPresident, Global Head of R&D2026-07-3115.9K shat $119.70 | Sale10b5-1 plan | $1.9M |
| Mohamed Khairie IssaEVP, Head of U.S. Commercial2026-07-161.1K shat $115.01 | Sale10b5-1 plan | $125.7K |
| Steven H SteinCMO & Head of Late-Stage Dev.2026-07-161.9K shat $114.73 | Sale10b5-1 plan | $215.3K |
| Steven H SteinCMO & Head of Late-Stage Dev.2026-07-1528.2K shat $113.05 | Sale10b5-1 plan | $3.2M |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on INCY
Follow Incyte Corp (INCY) by email
New trades in Incyte Corp (INCY) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.